News

September 20, 2019September 20, 2019

FDA OKs Use of Tool to Predict Patient Response to New Form of Cisplatin in Planned Phase 3 Study

News

The U.S. Food and Drug Administration (FDA) has approved use of a device, called LiPlaCis DRP, that works to predict response to the next-generation investigational chemotherapy LiPlaCis in a planned Phase ... Read more

September 18, 2019

Herceptin Developers Granted 2019 Lasker-DeBakey Research Award

News

The 2019 Lasker-DeBakey Clinical Medical Research Award has been granted to scientists H. Michael Shepard, PhD, Dennis J. Slamon, MD, PhD, and Axel Ullrich, PhD, for their development of the breast ... Read more

September 16, 2019

TNBC Patient Given Investigative Antibody, Leronlimab, Under Emergency Exception

News

A metastatic triple-negative breast cancer (TNBC) patient is being treated with CytoDyn’s investigational leronlimab (PRO 140) under an emergency investigational new drug (IND) application granted by the U.S. Food ... Read more

September 13, 2019September 13, 2019

FDA to Review Nerlynx Combo as Third-line Treatment for HER2-positive Metastatic Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has agreed to review Puma Biotechnology’s application seeking approval of Nerlynx (neratinib), in combination with capecitabine, to treat HER2-positive breast cancer patients with metastatic disease, ... Read more

September 11, 2019

Music Helps Ease Pain and Fatigue of Breast Cancer, Study Shows

News

Listening to music at home can considerably ease the severity of symptoms related to breast cancer and its treatments, helping reduce the pain and fatigue patients experience, a trial reports. ... Read more

September 9, 2019September 9, 2019

Nerlynx Granted FDA’s Orphan Drug Status for Treating Breast Cancer with Brain Metastases

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Puma Biotechnology’s Nerlynx (neratinib) for the treatment of HER2-positive breast cancer in women with brain metastases. Between 10 to 15% ... Read more

September 6, 2019

Longer Use of Hormone Replacement Therapy Linked to Greater Breast Cancer Risk in Study

News

The longer women use hormone therapy after menopause the higher is their breast cancer risk over time, and this risk persists for more than a decade after stopping this ... Read more

September 4, 2019

FDA Urges Inclusion of Men in Clinical Trials for Breast Cancer Treatment

News

The U.S. Food and Drug Administration (FDA) has drafted a series of recommendations urging the inclusion of men in breast cancer clinical trials, aiming to broaden treatment options for ... Read more

August 30, 2019

Tecentriq-Abraxane Combo OK’d in EU to Treat Certain Advanced Triple-negative Breast Cancers

News

The European Commission has approved the use of Roche‘s Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) chemotherapy to treat certain adults with advanced triple-negative breast cancer (TNBC), an aggressive and difficult-to-treat malignancy. ... Read more

August 28, 2019

USPSTF Updates Recommendations on Testing for BRCA-related Cancers in Women

News

The United States Preventive Services Task Force (USPSTF) has revised their recommendations on testing for cancer-associated BRCA1/2 mutations in women, suggesting risk assessment only in those with a personal or ... Read more

Pin It on Pinterest